The History of Terrorism
Preview
Open in TheBrain
Daniel O'Day
Attachments
Daniel O’Day
Parents
1754-Today Columbia University
1789-Today Georgetown University
CEOs of Roche Diagnostics
CEOs of Roche Pharmaceuticals
Chairmen of the Board of Gilead Sciences
Pharmaceutical lobbyists
Pharmaceutical Research and Manufacturers of America Board of Directors
Children
2020 "In the weeks since we learned of remdesivir's potential against Covid-19, one topic has attracted more speculation than any other: what price we might set for the medicine," O'Day wrote, before plunging into a masterpiece of corporate doublespeak.
2020 Daniel O'Day explained how much his company planned on charging for a course of remdesivir, one of many possible treatments for Covid-19.
2020 Rolling Stone - Big Pharma's Covid-19 Profiteers How the race to develop treatments and a vaccine will create a historic windfall for the industry - and everyone else will pay the price
In the U.S., he wrote, "earlier hospital discharge would result in hospital savings of approximately $12,000 per patient."
The CEO noted a study by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, showing that Covid-19 patients taking remdesivir recovered after 11 days, compared with 15 days for placebo takers.